Actively Recruiting
A Retrospective Study on the Hepatic Safety of Statin Use in Neurology Inpatients
Led by Shanghai Yueyang Integrated Medicine Hospital · Updated on 2024-09-19
2000
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the liver safety of statin use among inpatients in the neurology department in China. This study uses both a cross-sectional design and a retrospective cohort study to analyze statin effects from different perspectives. The goal is to provide additional evidence-based guidance for clinical use of statins in patients with neurological conditions, including cerebrovascular disease, headache, dizziness, and vertigo. The research consists of two phases. First, a cross-sectional study examines the relationship between statin use before hospital admission and the initial liver enzyme levels of patients. Next, a retrospective cohort study divides patients who were not on statins prior to admission into two groups based on whether they started statins after admission. Liver enzymes such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are measured four weeks after admission to assess liver safety. Participants are hospitalized adults aged 18 to 85 years with specific neurological diagnoses. Researchers review medical histories and liver enzyme tests, focusing on AST and ALT levels four weeks after admission. The study excludes patients with incomplete medical records, short prior statin use, malignant tumors, or blood diseases. The total participation involves data analysis from hospital records during the defined study period from June 2020 to February 2023.
CONDITIONS
Brief Title
Hepatic Safety of Statin Use in Neurology Inpatients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023
- Age 18 to 85 years, any gender
- Diagnosed with cerebrovascular disease, headache disease, or dizziness and vertigo according to ICD-11 criteria
You will not qualify if you...
- Incomplete medical history
- Prior statin use less than 7 days before admission
- Patients with malignant tumors
- Patients with hematological diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At admission
Participants' liver enzyme levels are assessed to understand the correlation with prior statin use before hospital admission.
1 visit (in-person)
Duration - 4 weeks after admission
Participants who started statin use after admission are monitored for liver enzyme changes over 4 weeks.
Follow-up visits during the 4 weeks after admission
Trial Site Locations
Total: 1 location
1
Shanghai Yueyang Integrated Medicine Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here